VitaFlow Liberty
Commercial- Indications
- Aortic valve stenosis
Company intelligence / Profile preview
MicroPort CardioFlow Medtech has successfully commercialized its VitaFlow series of transcatheter aortic valve implantation (TAVI) products globally. The VitaFlow Liberty system received EU CE-MDR Mark in early 2024. Over ten thousand patients have been treated with their devices across more than twenty countries. Clinical data show high safety and efficacy for their flagship products, including low stent thrombus rates and high durability due to proprietary anti-calcification technology.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MicroPort CardioFlow Medtech.